We are analyzing https://link.springer.com/article/10.1186/s13046-019-1259-z.

Title:
Combination of CTLA-4 and PD-1 blockers for treatment of cancer | Journal of Experimental & Clinical Cancer Research
Description:
Targeting checkpoints of immune cell activation has been demonstrated to be the most effective approach for activation of anti-tumor immune responses. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), both inhibitory checkpoints commonly seen on activated T-cells have been found to be the most reliable targets for the treatment of cancer. Six drugs targeting PD-1 or its ligand PD-L1 and one drug targeting CTLA-4 have been approved for treatment of different types of cancers and several others are in advanced stages of development. The drugs when administered as monotherapy had dramatic increase in durable response rates and had manageable safety profile, but more than 50% of patients failed to respond to treatment. Combination of CTLA-4 and PD-1 blockers was then evaluated to increase the response rates in patients, and ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) combination was shown to significantly enhance efficacy in metastatic melanoma patients. Subsequently, ipilimumab plus nivolumab was approved for treatment of metastatic melanoma, advanced renal cell carcinoma and metastatic colorectal cancer with MMR/MSI-H aberrations. The success of combination encouraged multiple clinical studies in other cancer types. Efficacy of the combination has been shown in a number of published studies and is under evaluation in multiple ongoing studies. This review aims to support future research in combination immunotherapy by discussing the basic details of CTLA-4 and PD-1 pathways and the results from clinical studies that evaluated combination of CTLA-4 and PD-1/PD-L1 blockers.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

pubmed, article, google, scholar, nivolumab, ipilimumab, cancer, combination, cas, patients, ctla, melanoma, phase, cell, study, central, advanced, oncol, metastatic, efficacy, treatment, med, cells, versus, blockade, trial, response, studies, therapy, lung, engl, immune, activation, table, lancet, pembrolizumab, clinical, death, rates, carcinoma, group, blockers, survival, monotherapy, showed, tcells, pdl, immunotherapy, adverse, treated,

Topics {✒️}

dna mismatch repair-deficient cis-pd-l1/cd80 interactions gastro-oesophageal junction cancer d'angelo sp microsatellite instability high itim motif-carrying immunoreceptor small-cell lung cancer article download pdf advanced renal-cell carcinoma pd-1 receptor-deficient mice immune-related adverse event recurrent squamous-cell carcinoma stimulating t-cell proliferation monoclonal anti pd-1antibodies immune-related adverse events anti-tumor immune responses drug targeting ctla-4 sustains t-cell anergy dna repair deficiency anti-tumor immune response anti-ctla-4 antibodies resulted dna-repair defects anti-pd-1/pd-l1 pd-1/pd-l1 pathway �high-risk’ melanoma [31 merkel cell cancer �real-world’ outcomes showed article rotte reliable therapeutic options immune-mediated adverse events pd-l1 negative tumors renal cell carcinoma hodi fs metastatic colorectal cancer hellmann md anand rotte peripheral t-cell tolerance privacy choices/manage cookies pd-l1 positive tumors durable clinical benefit pd-1/pd-l1 blockers immune checkpoint inhibitors wolchok jd springer international publishing metastatic esophagogastric cancer gastroesophageal junction cancer low-dose ipilimumab combination ctla-4-deficient mice creative commons license ipilimumab/nivolumab combination therapy

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Combination of CTLA-4 and PD-1 blockers for treatment of cancer
         description:Targeting checkpoints of immune cell activation has been demonstrated to be the most effective approach for activation of anti-tumor immune responses. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), both inhibitory checkpoints commonly seen on activated T-cells have been found to be the most reliable targets for the treatment of cancer. Six drugs targeting PD-1 or its ligand PD-L1 and one drug targeting CTLA-4 have been approved for treatment of different types of cancers and several others are in advanced stages of development. The drugs when administered as monotherapy had dramatic increase in durable response rates and had manageable safety profile, but more than 50% of patients failed to respond to treatment. Combination of CTLA-4 and PD-1 blockers was then evaluated to increase the response rates in patients, and ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) combination was shown to significantly enhance efficacy in metastatic melanoma patients. Subsequently, ipilimumab plus nivolumab was approved for treatment of metastatic melanoma, advanced renal cell carcinoma and metastatic colorectal cancer with MMR/MSI-H aberrations. The success of combination encouraged multiple clinical studies in other cancer types. Efficacy of the combination has been shown in a number of published studies and is under evaluation in multiple ongoing studies. This review aims to support future research in combination immunotherapy by discussing the basic details of CTLA-4 and PD-1 pathways and the results from clinical studies that evaluated combination of CTLA-4 and PD-1/PD-L1 blockers.
         datePublished:2019-06-13T00:00:00Z
         dateModified:2019-06-13T00:00:00Z
         pageStart:1
         pageEnd:12
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s13046-019-1259-z
         keywords:
            Immunotherapy
            CTLA-4
            PD-1
            Combination therapy
            Cancer Research
            Immunology
            Apoptosis
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-019-1259-z/MediaObjects/13046_2019_1259_Fig1_HTML.png
         isPartOf:
            name:Journal of Experimental & Clinical Cancer Research
            issn:
               1756-9966
            volumeNumber:38
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Anand Rotte
               affiliation:
                     name:Nevro Corp
                     address:
                        name:Clinical & Regulatory Affairs, Nevro Corp, Redwood City, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Combination of CTLA-4 and PD-1 blockers for treatment of cancer
      description:Targeting checkpoints of immune cell activation has been demonstrated to be the most effective approach for activation of anti-tumor immune responses. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), both inhibitory checkpoints commonly seen on activated T-cells have been found to be the most reliable targets for the treatment of cancer. Six drugs targeting PD-1 or its ligand PD-L1 and one drug targeting CTLA-4 have been approved for treatment of different types of cancers and several others are in advanced stages of development. The drugs when administered as monotherapy had dramatic increase in durable response rates and had manageable safety profile, but more than 50% of patients failed to respond to treatment. Combination of CTLA-4 and PD-1 blockers was then evaluated to increase the response rates in patients, and ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) combination was shown to significantly enhance efficacy in metastatic melanoma patients. Subsequently, ipilimumab plus nivolumab was approved for treatment of metastatic melanoma, advanced renal cell carcinoma and metastatic colorectal cancer with MMR/MSI-H aberrations. The success of combination encouraged multiple clinical studies in other cancer types. Efficacy of the combination has been shown in a number of published studies and is under evaluation in multiple ongoing studies. This review aims to support future research in combination immunotherapy by discussing the basic details of CTLA-4 and PD-1 pathways and the results from clinical studies that evaluated combination of CTLA-4 and PD-1/PD-L1 blockers.
      datePublished:2019-06-13T00:00:00Z
      dateModified:2019-06-13T00:00:00Z
      pageStart:1
      pageEnd:12
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s13046-019-1259-z
      keywords:
         Immunotherapy
         CTLA-4
         PD-1
         Combination therapy
         Cancer Research
         Immunology
         Apoptosis
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-019-1259-z/MediaObjects/13046_2019_1259_Fig1_HTML.png
      isPartOf:
         name:Journal of Experimental & Clinical Cancer Research
         issn:
            1756-9966
         volumeNumber:38
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Anand Rotte
            affiliation:
                  name:Nevro Corp
                  address:
                     name:Clinical & Regulatory Affairs, Nevro Corp, Redwood City, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Journal of Experimental & Clinical Cancer Research
      issn:
         1756-9966
      volumeNumber:38
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Nevro Corp
      address:
         name:Clinical & Regulatory Affairs, Nevro Corp, Redwood City, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Anand Rotte
      affiliation:
            name:Nevro Corp
            address:
               name:Clinical & Regulatory Affairs, Nevro Corp, Redwood City, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Clinical & Regulatory Affairs, Nevro Corp, Redwood City, USA

External Links {🔗}(386)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref
Pbgrd

7.12s.

LINK . SPRINGER . COM {}